Table 3.
Feature | Disease severity | P1 | P2*** | |||
---|---|---|---|---|---|---|
Mild/moderate (N = 33) | Severe (N = 139) | Critical (N = 28) | ||||
Laboratory findings | ||||||
Lymphopenia | 24 (75.0) | 99 (76.2) | 19 (70.4) | 0.985* | 0.818 | |
VBG pH | 7.42 ± 0.05 | 7.41 ± 0.05 | 7.10 ± 1.29 | 0.572** | 0.030 | |
VBG pO2 (mmHg) | 36.27 ± 9.11 | 32.21 ± 9.48 | 31.85 ± 8.51 | 0.037** | 0.021 | |
VBG pCO2 (mmHg) | 39.01 ± 6.81 | 40.33 ± 7.84 | 35.12 ± 7.92 | 0.824** | 0.112 | |
VBG pHCO3 (mmHg) | 25.86 ± 4.05 | 25.94 ± 5.05 | 23.14 ± 4.32 | 0.705** | 0.054 | |
AST (IU/L) | 57.92 ± 76.53 | 48.55 ± 74.94 | 54.42 ± 31.50 | 0.470** | 0.031 | |
ALT (IU/L) | 59.64 ± 87.35 | 50.94 ± 77.99 | 49.78 ± 60.37 | 0.210** | 0.384 | |
LDH (U/L) | 560.20 ± 200.34 | 660.74 ± 434.76 | 897.70 ± 287.47 | 0.310** | 0.137 | |
CRP (mg/L) | 51.64 ± 52.07 | 86.22 ± 62.33 | 167.59 ± 146.86 | 0.003** | 0.001 | |
Chest CT findings | ||||||
Consolidation | None | 8 (24.2) | 36 (25.9) | 5 (17.9) | 0.009* | 0.002 |
1 lobe | 1 (3.0) | 3 (2.2) | 0 (0.0) | |||
2 lobes | 21 (63.6) | 55 (39.6) | 6 (21.4) | |||
3 lobes | 0 (0.0) | 1 (0.7) | 2 (7.1) | |||
4 lobes | 3 (9.1) | 44 (31.7) | 15 (53.6) | |||
GGO | None | 7 (21.2) | 32 (23.0) | 9 (32.1) | < 0.001* | < 0.001 |
1 lobe | 3 (9.1) | 0 (0.0) | 0 (0.0) | |||
2 lobes | 13 (39.4) | 25 (18.0) | 6 (3.6) | |||
3 lobes | 0 (0.0) | 4 (2.9) | 0 (0.0) | |||
4 lobes | 10 (30.3) | 78 (56.1) | 18 (64.3) | |||
PE | 1 (3.0) | 8 (5.8) | 4 (14.3) | 0.376* | 0.168 | |
Bronchiectasis | 0 (0.0) | 1 (0.7) | 0 (0.0) | 0.656* | 0.802 |
VBG venous blood gas, AST aspartate aminotransferase, ALT alanine aminotransferase, LDH lactate dehydrogenase, CRP C-reactive protein, CT computed tomography, GGO ground-glass opacity, PE pleural effusion.
P1: Comparison between mild/moderate and severe/critical groups.
P2: Comparison between mild/moderate, severe, and critical groups.
Bold values are statistically significant (P < 0.05).
*Chi-square or Fisher’s exact test.
**Mann–Whitney test.
***Kruskal–Wallis test.